Mitochondrial Diseases Clinical Trial
Official title:
An Intermediate Size Expanded Access Protocol of Elamipretide for Subcutaneous Injection in Patients With Genetically Confirmed Rare Diseases With Known Mitochondrial Dysfunction
NCT number | NCT04689360 |
Other study ID # | SPIES-006 |
Secondary ID | SPIES-007 |
Status | Available |
Phase | |
First received | |
Last updated |
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor to learn more about this program. The treating physician must contact StealthBiotherapeutics using the Expanded Access Program Contacts provided. Elamipretide will only be made available after careful review of an individual request submitted by the treating physician. The initiation and conduct of the treatment with elamipretide for an individual patient, and compliance with this treatment guideline, will be under the full and sole responsibility of the treating physician.
Status | Available |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | All |
Age group | 1 Year to 80 Years |
Eligibility | Key Inclusion Criteria: 1. =1 year and = 80 years of age or =12 years for Barth Syndrome in SPIES-007 2. Patients with genetically confirmed rare primary mitochondrial diseases including Barth Syndrome 1. observed cardiomyopathy, renal impairment, neuropathic, or ophthalmic manifestation 2. where such disease is serious or life-threatening and no comparable or satisfactory alternative therapy options available. 3. Patients without genetic confirmation of a rare disease with known mitochondrial dysfunction but do exhibit serious or life-threatening clinical manifestations of mitochondrial dysfunction. 4. Is self-able or has caregiver willing and able to administer SC injection. 5. Would potentially benefit from treatment with elamipretide and cannot be treated satisfactorily with any approved medicinal product in the opinion of the treating physician. Key Exclusion Criteria: 1. Known hypersensitivity to elamipretide or any excipients. 2. Women who are pregnant, are planning on becoming pregnant, or are breast-feeding. 3. Patients receiving any other investigational agent within 30 days of dosing. 4. Any active, serious psychiatric, medical, or other conditions/situations which, in the treating physician's opinion, could compromise the patient's safety. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Stealth BioTherapeutics Inc. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03388528 -
Low Residue Diet Study in Mitochondrial Disease
|
N/A | |
Completed |
NCT04378075 -
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
|
Phase 2/Phase 3 | |
Completed |
NCT03678740 -
Diagnostic Odyssey Survey 2
|
||
Recruiting |
NCT06051448 -
Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).
|
Phase 1/Phase 2 | |
Completed |
NCT02909400 -
The KHENERGY Study
|
Phase 2 | |
Completed |
NCT02398201 -
A Study of Bezafibrate in Mitochondrial Myopathy
|
Phase 2 | |
Completed |
NCT03857880 -
Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip
|
||
Not yet recruiting |
NCT06450964 -
Establishment of Reproductive Cohort and Prediction Model of Genetic Counseling for Mitochondrial Genetic Diseases
|
||
Completed |
NCT04165239 -
The KHENERGYZE Study
|
Phase 2 | |
Completed |
NCT02284334 -
Glycemic Index in Mitochondrial Disease
|
||
Recruiting |
NCT06080568 -
Human Mitochondrial Stress-driven Obesity Resistance
|
||
Recruiting |
NCT06080581 -
Mitochondrial Dysfunctions Driving Insulin Resistance
|
||
Recruiting |
NCT04802707 -
Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome
|
Phase 2 | |
Completed |
NCT04580979 -
Natural History Study of FDXR Mutation-related Mitochondriopathy
|
||
Completed |
NCT04594590 -
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy
|
||
Withdrawn |
NCT03866954 -
Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy
|
Phase 2 | |
Recruiting |
NCT04113447 -
Mitochondrial Donation: An 18 Month Outcome Study.
|
||
Enrolling by invitation |
NCT04734626 -
CrCest Study in Primary Mitochondrial Disease
|
||
Completed |
NCT03832218 -
Executive Function Disorders and Anxio-depressive Symptomatology in Children and Adolescents With Mitochondrial Pathologies
|
N/A | |
Terminated |
NCT02473445 -
A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
|
Phase 2 |